Journal article

Targeted Nanoparticle Delivery of Doxorubicin Into Placental Tissues to Treat Ectopic Pregnancies

Tu'uhevaha J Kaitu'u-Lino, Scott Pattison, Louie Ye, Laura Tuohey, Pavel Sluka, Jennifer MacDiarmid, Himanshu Brahmbhatt, Terrence Johns, Andrew W Horne, Jeremy Brown, Stephen Tong



Abnormal trophoblast growth can cause life-threatening disorders such as ectopic pregnancy, choriocarcinoma, and placenta accreta. EnGeneIC Delivery Vehicles (EDVs) are nanocells that can promote tissue-specific delivery of drugs and may be useful to medically treat such disorders. The objective of this study was to determine whether EDVs loaded with the chemotherapeutic doxorubicin and targeting the epidermal growth factor receptor (EGFR, very highly expressed on the placental surface) can regress placental cells in vitro, ex vivo, and in vivo. In female SCID mice, EGFR-targeted EDVs induced greater inhibition of JEG-3 (choriocarcinoma cells) tumor xenografts, compared with EDVs targeting a..

View full abstract


Awarded by National Health and Medical Research Council of Australia

Awarded by Medical Research Council

Funding Acknowledgements

This study was financially supported by The National Health and Medical Research Council of Australia (Project Grant No. 606611; Salary support No. 490970, No. 490995); Helen MacPherson Trust; Strategic Grants Scheme Monash University; and The Victorian Government's Operational Infrastructure Support Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.